Management of newly diagnosed metastatic carcinoma of the prostate.
Metastatic prostatic cancer can be present in a variety of different ways. The authors describe the differences among stages D-0, D-1, and D-2 disease and present the treatment options for each of the substages. They summarize and integrate the clinical evidence that bears on the potential efficacy of each treatment.
D000135:Acid Phosphatase / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D002369:Castration; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011867:Radioisotope Teletherapy
D000970:Antineoplastic Agents; D004967:Estrogens; D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol; D000135:Acid Phosphatase; D016729:Leuprolide